

Seat No.: _____

Enrolment No. _____

GUJARAT TECHNOLOGICAL UNIVERSITY
M. Pharm. – SEMESTER – III • EXAMINATION – WINTER • 2015

Subject Code: 1931501

Date: 08-12-2015

Subject Name: Drug Regulation and Regulatory Authority

Time: 10:30 am - 01:30 pm

Total Marks: 80

Instructions:

- 1. Attempt any five questions.**
- 2. Make suitable assumptions wherever necessary.**
- 3. Figures to the right indicate full marks.**

- | | | | |
|-------------|------------|--|-----------|
| Q.1 | (a) | Give a brief account on Drug Master File. | 06 |
| | (b) | Give a brief note on WHO certification Scheme on Pharmaceuticals. | 05 |
| | (c) | Write note on Good Clinical Practice as per US. | 05 |
| Q.2 | (a) | What are the different regulatory consideration for evaluation of Clinical Parameters? | 06 |
| | (b) | Give a note on Harmonization of Pharmaceutical Standards. | 05 |
| | (c) | Give in detail criteria for designing clinical trials for Geriatric Population. | 05 |
| Q.3 | (a) | Write a note on NPPA. | 06 |
| | (b) | Write a note on recent amendments in D & C Act. | 05 |
| | (c) | Write a note on procedure required for New Drug Application as per US. | 05 |
| Q.4 | (a) | Write a note on IP Review Process. | 06 |
| | (b) | Give a brief note on Haemovigilance Programme. | 05 |
| | (c) | Write in detail ICH E8 guidelines. | 05 |
| Q.5 | (a) | Give in detail parameters to be considered for formation of monograph. | 06 |
| | (b) | Give different types of Toxicity Studies. Give a note on Immunotoxicity and Genotoxicity | 05 |
| | (c) | Give brief account on Pharmacovigilance Programme in Indian perspective. | 05 |
| Q. 6 | (a) | Give a note on medical device application procedure as per US. | 06 |
| | (b) | Give Brief note on electronic CTD. | 05 |
| | (C) | Give a note on NDA filling as per Schedule Y. | 05 |
| Q.7 | (a) | Give a current Price fixation Procedure for Pharmaceutical drugs. | 06 |
| | (b) | Give a note on Documents required for clinical trial application Schedule Y. | 05 |
| | (c) | Give a note on document required for new drug application as per EUDRA guidelines. | 05 |
